Bifunctional Molecule for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods using monoclonal full-length antibodies for T cell activation require complex preparation processes, increased workload, and higher production costs due to the need for separate expression and purification of anti-CD3 and anti-costimulatory molecule antibodies.
Innovation Solution
A bifunctional molecule is developed by fusing a domain that binds and activates CD3 with a domain that binds and activates CD28 or other costimulatory molecules, simplifying the production process and reducing costs while maintaining effective T cell activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal full-length antibodies are used for T cell activation, then effective T cell activation is achieved, but the preparation process becomes complex and production costs increase
Solution Approach 1:
The patent combines anti-CD3 antibody and anti-costimulatory molecule antibody into a single bifunctional molecule. This merging eliminates the need for separate expression and purification of two antibodies, thereby simplifying the preparation process while maintaining the dual signaling function required for effective T cell activation
Solution Approach 2:
The bifunctional molecule serves multiple functions simultaneously: it provides both the first signal through CD3 binding and the second costimulatory signal through costimulatory molecule binding. This multi-functionality in a single molecule resolves the contradiction by maintaining activation effectiveness while reducing process complexity
2Reliability
If monoclonal full-length antibodies are used for T cell activation, then effective T cell activation is achieved, but workload increases
Solution Approach 1:
By merging two separate antibody functions into one bifunctional molecule, the patent reduces the workload associated with expressing, purifying, and optimizing ratios of two separate antibodies. The single molecule approach streamlines the workflow while preserving the dual-signal activation mechanism
3Reliability
If monoclonal full-length antibodies are used for T cell activation, then effective T cell activation is achieved, but production costs increase
Solution Approach 1:
The patent merges two antibody production processes into one for the bifunctional molecule. This consolidation reduces manufacturing steps, lowers production costs, and maintains the therapeutic effectiveness by preserving both CD3 and costimulatory molecule binding capabilities in a single molecule
4Device complexity
If bifunctional molecule is used, then production process is simplified and costs reduced, but protein dosage must be optimized
Solution Approach 1:
The patent adjusts the dosage parameter of the bifunctional molecule to optimize T cell expansion efficiency. By systematically evaluating different concentrations, the study determines the optimal dosage that maximizes therapeutic effect while accounting for the simplified single-molecule structure
Data Source
AI summary
This disclosure belongs to the field of biomedical technology, and particularly refers to a bifunctional molecule and the application thereof. The structure of the bifunctional molecule includes a first functional domain and a second functional domain. These domains are capable of simultaneously binding to T cells, thereby producing the first and second signals required for T cell activation. The bifunctional molecule is a recombinant protein-peptide, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and stable preparation process and product. The bifunctional molecule is superior to the current techniques in expanding T cells in vitro with lower protein dosage and simpler use procedure. It can be directly supplemented as soluble form without optimizing the relative ratio of full-length antibodies.